Journal of Clinical Endocrinology & Metabolism, Vol 79, 1376-1382, Copyright © 1994 by Endocrine Society

ARTICLES

Alteration in insulin-like growth factor-binding proteins (IGFBPs) and IGFBP-3 protease activity in serum and urine from acute and chronic renal failure

DY Lee, SK Park, PD Yorgin, P Cohen, Y Oh and RG Rosenfeld
Department of Pediatrics, Chonbuk National University Medical School, Chonju, Korea.

The insulin-like growth factors, IGF-I and IGF-II, are proteins that promote cellular growth and differentiation of various organs, including the kidney. These peptides interact with high affinity cell surface receptors and bind to a family of IGF-binding proteins (IGFBPs). Altered serum and urinary IGFBP patterns in children with chronic renal failure have been previously described. In this study, we evaluated serum and urinary IGFBP profiles in acute renal failure patients (ARF; n = 10) and chronic renal failure patients (n = 10), using Western ligand blots. Most patients with acute or chronic renal failure showed decreased intact serum IGFBP-3 and increased serum IGFBP- 2. Both groups displayed marked urinary IGFBP alterations, including increased urinary IGFBP-1 and totally absent urinary IGFBP-3, as detected by Western ligand blot. To evaluate altered IGFBP profiles, we performed IGFBP-3 protease assays with sera and urine from renal failure patients and normal controls. Although control urine had only minor protease activity (defined by the ability to degrade [125I]IGFBP- 3), significant protease activity was found in urine from renal failure patients. The proteolytic pattern and susceptibility to protease inhibitors in most renal failure urine samples were the same as those seen in normal urine and with plasmin. Protease activity was completely inhibited by serine protease inhibitors. We speculate that urinary protease activity is mediated primarily by a serine protease(s), which may be involved in the modulation of renal IGF activity in health and disease.

This article has been cited by other articles:

				X. Wang, M. D. Hollenberg, and R. Loutzenhiser Redundant signaling mechanisms contribute to the vasodilatory response of the afferent arteriole to proteinase-activated receptor-2 Am J Physiol Renal Physiol, January 1, 2005; 288(1): F65 - F75. [Abstract] [Full Text] [PDF]

				Y. Wu, K. Cui, K. Miyoshi, L. Hennighausen, J. E. Green, J. Setser, D. LeRoith, and S. Yakar Reduced Circulating Insulin-like Growth Factor I Levels Delay the Onset of Chemically and Genetically Induced Mammary Tumors Cancer Res., August 1, 2003; 63(15): 4384 - 4388. [Abstract] [Full Text] [PDF]

				M. Shinada, A. Akdeniz, S. Panagiotopoulos, G. Jerums, and L. A. Bach Proteolysis of Insulin-Like Growth Factor-Binding Protein-3 Is Increased in Urine from Patients with Diabetic Nephropathy J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 1163 - 1169. [Abstract] [Full Text]

				A. Vijayan, S. C. Franklin, T. Behrend, M. R. Hammerman, and S. B. Miller Insulin-like growth factor I improves renal function in patients with end-stage chronic renal failure Am J Physiol Regulatory Integrative Comp Physiol, April 1, 1999; 276(4): R929 - R934. [Abstract] [Full Text] [PDF]

				S. Rajaram, D. J. Baylink, and S. Mohan Insulin-Like Growth Factor-Binding Proteins in Serum and Other Biological Fluids: Regulation and Functions Endocr. Rev., December 1, 1997; 18(6): 801 - 831. [Abstract] [Full Text]

				G. Trottier, M. Hollenberg, X. Wang, Y. Gui, K. Loutzenhiser, and R. Loutzenhiser PAR-2 elicits afferent arteriolar vasodilation by NO-dependent and NO-independent actions Am J Physiol Renal Physiol, May 1, 2002; 282(5): F891 - F897. [Abstract] [Full Text] [PDF]